Dysgerminoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors (NCT03158064) | Memorial Sloan Kettering Cancer Center | 2017-05-15 |
| Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) (NCT00204633) | University Hospital Tuebingen | 2003-07-01 |
Track Dysgerminoma automatically
Every clearance here is in the API, with alerts when new ones post.